Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 1000 [iu];  ;   - powder for injection with diluent - 1000 iu - active: rurioctocog alfa pegol 1000 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 2000 [iu];  ;   - powder for injection with diluent - 2000 iu - active: rurioctocog alfa pegol 2000 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 250 [iu];  ;   - powder for injection with diluent - 250 iu - active: rurioctocog alfa pegol 250 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 500 [iu];  ;   - powder for injection with diluent - 500 iu - active: rurioctocog alfa pegol 500 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 1500 [iu];  ;   - powder for injection with diluent - 1500 iu - active: rurioctocog alfa pegol 1500 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 3000 [iu];  ;   - powder for injection with diluent - 3000 iu - active: rurioctocog alfa pegol 3000 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 750 [iu];  ;   - powder for injection with diluent - 750 iu - active: rurioctocog alfa pegol 750 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

takeda new zealand limited - factor viii inhibitor bypassing fraction 1000 u;  ;   - powder for injection with diluent - 1000 u - active: factor viii inhibitor bypassing fraction 1000 u     excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

takeda new zealand limited - factor viii inhibitor bypassing fraction 2500 u;  ;   - powder for injection with diluent - 2500 u - active: factor viii inhibitor bypassing fraction 2500 u     excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

takeda new zealand limited - factor viii inhibitor bypassing fraction 500 u;  ;   - powder for injection with diluent - 500 u - active: factor viii inhibitor bypassing fraction 500 u     excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.